Platelet-activating factor (PAF) is a phospholipid with cardiovascular actions at low concentrations (1-100 nM) but with uncertain direct myocardial actions. We investigated the cellular and molecular effects of PAF on heart cells using isolated adult and neonatal rat myocytes. 
Introduction
Platelet-activating factor (PAF', I-O-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine) is a potent signaling molecule whose biological activity was initially associated with platelet activation (1, 2) . This phospholipid is now known to have profound ef-fects on many tissues including muscle cells, vascular tissue, and neurons (3) (4) (5) . PAF can be synthesized in and released from many tissues including kidney, lung, and heart, as well as from cells in the circulation in response to appropriate stimuli (3, (6) (7) (8) . Biochemical investigation into the biosynthesis of PAF indicates that heart muscle could be exposed to this molecule in a physiological setting. In this regard, recent studies have reported that significant quantities ofPAF were measured in coronary effluent after an ischemic intervention (9, 10) .
Despite this evidence, there has been confusion concerning the action of PAF on cardiac tissue. In recent studies, PAF has been reported to have little or no direct action on the myocardium (10, 1 1). It was proposed that the cardioactive effects of PAF arise secondarily to platelet-dependent release of cardioactive agents (thromboxane A2, histamine, and leukotrienes). In contrast, in earlier studies using electrically paced isolated cardiac tissue, a case was made for direct action ofPAF on the heart (12, 13) . Detailed information concerning the action ofthis phospholipid in cardiac cells has been limited by the complex tissue and cellular systems used in these experiments.
In this study isolated adult and neonatal rat heart cells were used to investigate the actions of PAF on a cardiac tissue uncomplicated by other cell types. We report here that PAF exerts a direct negative inotropic effect on such cells and that this effect is mediated by a specific cardiac PAF receptor. Furthermore, we suggest that the functional changes in heart cells produced by PAF arise from the activation of protein kinase C via the phospholipase C/phosphatidylinositol intracellular signaling pathway.
Methods
Preparation of cardiac myocytes. Isolated single cells from adult rat cardiac ventricular tissue were prepared by enzymatic disaggregation of the intact tissues. The cells were placed in a four-well 1.7-cm culture dish. After 30 min the cells settled to the bottom of the plate and were used the same day (14) . Spontaneously beating primary cultures of neonatal rat cardiac ventricular myocytes were prepared from l-d old Sprague-Dawley rats (15) . The cells were plated in four-well 1.7-cm tissue culture dishes and grown in culture for 4-5 d (15) (16) (17) .
Measurement of contractile properties of adult or neonatal cells. Contractions of single cardiac myocytes, in four-well culture dishes, were measured using an optical video dimension analysis system as previously described (15) . Briefly, the four-well culture dish was mounted on the stage ofan inverted phase microscope and the cells in a single well were superfused at 1 ml/min with control medium (DME, 25 were labeled with 10 MACi/ml of [3H]myo-inositol for 24 h in serum-free DME-Hepes, 0.25% BSA, unless otherwise indicated. Pilot studies revealed that the absence of serum during the labeling phase had no qualitative effects on the biochemical or biological responses reported in Results. However, serum-free media greatly improved the signal in the assay. At the time of the experiment the cells were washed with 4 x 0.5 ml DME-Hepes, 0.25% BSA, and treated as indicated in Results. After aspirating the supernatant, the reaction was stopped by rapidly adding 0.5 ml of 6% perchloric acid at 0C. The acid extract was neutralized and the [3H]inositol phosphates were resolved using ion exchange chromatography as described previously (15 (12, (18) (19) (20) and has been proposed as a promotor of ischemia-reperfusion injury by both direct and indirect action (21) (22) (23) .D lar myocytes. This well defined cardiac preparation allows for molecular and functional studies to be performed in parallel (15) (16) (17) . Fig. 2 shows that spontaneously contracting heart cells superfused with 80 nM PAF exhibited a rapid increase in the beating rate (66% over 2 min). Decreases in amplitude (50%) and in maximum contraction/relaxation velocities were also observed in this representative experiment. The addition of PAF in several experiments showed an average maximal increase in spontaneous beating rate of 72±5.4% above control values (mean±SEM, n = 7). The average decrease in amplitude was 39±4.6% below control values (mean±SEM, n = 7).
Since it is possible that the PAF-mediated decreases in both velocity and amplitude result from the increases in contractile frequency, the action of PAF on myocytes at a fixed frequency was investigated. Fig. 3 shows that when myocytes were electrically driven at 90 beats per min, application of 20 nM and 80 nM PAF resulted in a rapid decrease in twitch amplitude. The results from a series ofexperiments revealed that 20 nM and 80 nM PAF decreased twitch amplitude by 32±6.3% and 24±8.8%, respectively (mean±SEM, n = 5-6), values which are not statistically different. Fig. 3 also shows that the overall shape of the twitch is not altered by 80 nM PAF. These results demonstrate that the effects of PAF on electrically driven neonatal myocytes are similar to the responses observed in adult heart cells. However, the negative inotropic effects of PAF are reduced in paced neonatal cells compared to spontaneous beating neonatal myocytes. Taken together, these data suggest that some of the action of PAF is rate related, but the negative inotropic effects of PAF cannot be explained on the basis of rate change alone.
To investigate the possibility that the functional responses we have observed are receptor mediated, the potency and specificity of the PAF effects were characterized. The effects of PAF on both frequency and amplitude were dose dependent. As shown in Fig. 4 , PAF was very potent in evoking functional responses, with 1 nM PAF increasing frequency by > 20% over control. The dose-response relation was biphasic, with an initial phase between 0.5 nM and 20 nM and a second phase between 20 nM and 100 nM. Contractile amplitude in the second phase decreased by up to 65%. Fig. 5 shows that the biologically inactive analogue of PAF, lyso-PAF, had no effect on contractile behavior, even at concentrations as high as 100 nM.
The specificity ofthe PAF-evoked effects was further examined by the use ofa potent PAF receptor antagonist, BN 50739 (24) . Before application of 20 nM PAF, cells were pretreated with various concentrations ofBN 50739 for 10 min. As shown in Fig. 6 , BN 50739 was very potent in blocking the functional responses ofthe cells to PAF, with half-maximal doses in the 10 nM range. If the inhibitory effects of BN 50739 are due to its action at the level ofthe receptor, then the inhibition should be competitive in character. To test this hypothesis, a PAF doseresponse curve was generated in the presence ofa half-maximal dose of BN 50739 (10 nM). As shown in Fig. 7 , addition of BN 50739 caused a displacement of the PAF dose-response curve to the right by about one order of magnitude, without altering the maximal response of the cells at high doses of PAF. These results support the view that PAF and BN 50739 compete for a common receptor site. Taken together, they indicate that there is a specific cardiac PAF receptor that mediates the negative inotropic action of this phospholipid.
These results suggest that there are specific PAF-receptor mediated intracellular molecular mechanisms that underlie the potent biological effects of PAF (25) , an important issue arises concerning the pharmacological characteristics of the cardiac receptor. Measurements of phosphoinositide turnover were employed to characterize the pharmacology of the cardiac PAF receptor by using the inhibitory potencies of different PAF antagonists as an index oftheir affinities for the PAF receptor. As shown in Fig. 10 , BN 50739 was most potent and SRI 63-441 was about 10-fold less potent (ICv-50 nM). Brotizolam, RO 19-3704/001, and WEB 2086 were also less potent with IC~v's in the range of 100-300 nM. The ginkgolide antagonist, BN 52021, was not an effective blocker, even at doses of 1 gM (data not shown).
The rank order of potency ofthese drugs is consistent with the relative affinities of these antagonists for the PAF receptor in platelets (26) . This demonstrates that: (a) there are potent antagonists ofthe cardiac PAF receptor; and (b) the pharmacology of the cardiac PAF receptor is similar to that characterized in platelets.
The results presented above suggest that a second messenger derived from the phosphoinositide pathway mediates the functional responses ofPAF. Further, the responses to PAF are similar to those with agents that are known to stimulate protein kinase C in these cultures (15, 16) . To examine the hypothesis that protein kinase C mediates the effects of PAF, experiments were designed using cells that were depleted of this enzyme. Myocytes were treated overnight with the phorbol ester, TPA
(1 gM). We have previously shown that in neonatal myocytes under these conditions there is > 96% loss of enzyme activity (17) . These cultures were exposed to 25 nM PAF, a dose that maximally stimulated phosphoinositide turnover. As shown in Fig. 11 , PAF did not evoke functional changes in these cells; application of25 nM PAF had no effect on either the frequency (34 beats per min) or the amplitude ofcontraction. The signalaveraged twitches underscore the lack of response of protein kinase C-depleted cells to PAF. The failure of such cells to respond to PAF might result from a lack ofa phosphoinositide response. However, as shown in Fig. 12 , PAF stimulated the production ofinositol phosphates in protein kinase C-depleted cells in a manner analogous to that in normal cells. These data support the conclusion that protein kinase C, rather than Ins(1,4,5)P3, is an important mediator ofthe effects of PAF on cardiac cells.
Discussion
The ability ofPAF to adversely affect cardiac function has been well documented in the literature (3, 27) . Yet the physiological importance of this phospholipid in cardiac disease has been difficult to establish due to the complex experimental models used. For example, administration ofexogenous PAF to laboratory animals leads to cardiac dysfunction (18) (19) (20) 28) . However, this agent alters vascular tone, activates the sympathetic nervous system, and stimulates most cells ofthe systemic circulation (3, 7, 8, 27) . Thus, it is difficult to delineate specific cardiac effects in such models. Other experimental evidence implicates PAF alterations in cardiac function. PAF receptor antagonists are protective in models of myocardial ischemia (4, 22, 23) . More focused experiments with paced isolated human atrial tissue and guinea pig papillary muscle suggest that PAF has a direct negative inotropic effect (12, 13 ). Yet, other recent experiments have been interpreted to suggest that the effects of PAF on heart depend on platelet activation and release of secondary mediators (10, 1 1) . Thus, it is clear that other approaches are required in order to define the role of PAF in cardiac function and disease.
It was within this context that we initiated studies to examine the effects of PAF in isolated rat ventricular myocytes: a simplified cell system that contains no vascular, neuronal, or blood components. The principal findings ofthis report are: (a) PAF exerts a direct negative inotropic effect on myocardial tissue; (b) the effects of PAF are mediated by a specific, high affinity receptor located on myocardial cells; (c) an underlying Negative inotropic effects ofPAF. The initial studies were performed in electrically stimulated dissociated adult rat myocytes. PAF evoked a decrease in myocardial contractility characterized by a decrease in beating amplitude, velocity of contraction, and velocity of relaxation. Having documented a direct negative inotropic effect in adult cells, subsequent experiments were performed in cultures ofspontaneously beating neonatal rat myocytes. Here the functional studies produced results analogous to the responses observed in adult cells; decreases in beating amplitude, velocity of contraction, and velocity of relaxation.
In the spontaneously beating neonatal cell preparation, PAF also evoked a rapid increase in the beating frequency. It could be argued that in this cell system the PAF-mediated fall in myocardial contractility was the result ofincreased contractile frequency. However, when neonatal cells were electrically driven at a fixed rate, decreases in amplitude, velocity of contraction, and velocity of relaxation comparable to those observed in the adult cell preparation were still noted. Although part of the response in neonatal cells may be rate related, these results reveal that PAF is a negative inotropic agent in both isolated adult and neonatal rat ventricular cells.
Characterization ofa cardiac PAF receptor. A conclusion from the data reported here is that the effects of PAF are mediated by a specific, high affinity receptor located on cultured myocytes. PAF is potent in evoking cardiac responses, with threshold doses in the 1 nM range. Further, the effects of PAF on contractile behavior are dose-dependent and saturable, in respect to both frequency and amplitude. The dose-response relation was biphasic with an initial phase between 0.5 and 20 nM and a second phase between 20 and 100 nM. The doses seen in the initial phase are consistent with recent measurements of PAF in the circulation. PAF concentrations have been seen to increase from undetectable levels to 0.6-2 nM in two separate models: (a) in coronary effluent of isolated rabbit heart during initial reperfusion following an ischemic intervention; (b) in coronary sinus samples of patients with coronary artery disease undergoing atrial pacing (9, 10) . These data underscore the physiological relevance of the PAF-evoked responses reported here.
Examination of the specificity of the PAF effects provided further evidence for a cardiac receptor. The biologically inactive analogue of PAF, lyso-PAF, had no effect on contractile behavior. BN 50739, a potent synthetic PAF receptor antagonist (24) (16, (33) (34) (35) . The functional studies reported here suggest that the effects of PAF are mediated by protein kinase C because the effects noted are identical to those seen in previous studies with angiotensin II and phorbol esters (15, 16 (36) . Further, the expression and function ofsarcoplasmic reticulum, a target for protein kinase C, is not altered when compared to control cells (17) . Finally, in the present study PAF still activated the receptor-mediated phospholipase C pathway in depleted cells, demonstrated by the accumulation ofinositol phosphates, including Ins(1,4,5)P3. These data dissociate Ins(1,4,5)P3 production from the PAF-evoked functional effects and define an important role for protein kinase C in mediating the effects of PAF on heart cells.
Characterization ofcardioactive PAF antagonists. There is evidence for multiple receptors for PAF in several cells (25) . TO Thus, it was important to further characterize the pharmacological features of the cardiac PAF receptor. Measurements of phosphoinositide turnover were used to assess the potency of six known PAF antagonists as an index oftheir affinities for the receptor. The rank order of potency we noted in cardiac tissue is consistent with the relative affinities of these drugs for the PAF receptor in platelets, demonstrating that the cardiac receptor is similar pharmacologically to that observed in platelets (26) . Thus, this cell system can be used to evaluate the relative potency and potential cardiac efficacy ofa variety ofPAFantagonists.
In summary, the present results demonstrate that PAF decreases contractile behavior and increases phosphoinositide turnover in isolated rat ventricular myocytes. These effects are mediated by a specific cardiac PAF receptor which ultimately leads to the activation of protein kinase C. The receptor appears to be similar to that which has been identified in other tissues. Finally, with a potential role for PAF antagonists in the treatment ofischemia-reperfusion injury, this cultured cell system provides a valuable tool for assessing the relative efficacy of these antagonists.
